MabVax appoints Tom Varvaro to board
This article was originally published in Scrip
MabVax Therapeutics, a clinical-stage cancer immunotherapy company, has named Tom Varvaro to its board of directors as an independent director. The appointment of Mr Varvaro brings the total number of directors to seven. Mr Varvaro, age 45, has served as the CFO of ChromaDex since January 2004 and served as a director from March 2006 until May 2010. At ChromaDex, he is responsible for overseeing all aspects of the company's accounting, IT, intellectual property, and human resources.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.